RemeGen

North Chicago – October 18, 2026 -- AbbVie will present new and updated data on seven solid tumor assets at the 2026 European Society for Medical Oncology (ESMO) Congress, October 23-27 in Madrid, the company's most expansive ESMO program to date. The data span lung, colorectal, ovarian, prostate and gastric cancers, across antibody-drug conjugates (ADCs), bispecific antibodies and combination regimens.

Temab-A posts 30% response rate in colorectal cancer combination

In a Phase 1 study of previously treated advanced colorectal cancer, Temab-A (telisotuzumab adizutecan) at 2.4 mg/kg plus bevacizumab delivered a 30% overall response rate after a median follow-up of 18.2 months. Median overall survival reached 14.7 months with the combination (n=30), against 10.2 months for standard of care (n=20), regardless of c-Met expression. No new safety signals were observed. The combination is now in the global Phase 3 AndroMETa-CRC-560 study.